SCHEMBL5120716

SCHEMBL5120716

O=C(O)NS(=O)(=O)NC1CCCCC1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.64
CA7 P43166 3/20 0.64
CA14 Q9ULX7 3/20 0.64
CA1 P00915 2/20 0.64
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.47
EPHX1 P07099 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 1/20 0.41
EPHX2 P34913 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25181552 0.89 CA12 (0.59) CA12CA7CA14CA1CA2
SCHEMBL3214272 0.80 CA12 (0.48) CA12CA7CA14CA1CA9
SCHEMBL3273296 0.79 CA12 (1.00) CA12CA7CA14CA1CA2
SCHEMBL12421786 0.74 CA12 (0.52) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL4602644 0.72 CA1 (0.54) CA12CA7CA14CA1CA2
SCHEMBL13400569 0.72 CA12 (0.53) CA12CA7CA14CA1CA2
SCHEMBL1706356 0.71 CA12 (0.83) CA12CA7CA14CA1CA2
SCHEMBL20125180 0.71 CA12 (0.73) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL3790764 0.71 CA1 (0.52) CA12CA7CA14CA1CA2
SCHEMBL22403974 0.71 CA12 (0.50) CA12CA7CA14CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 CA12 1162/4885CA7 166/4885CA14 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.